Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Default user image.

Jan Nilsson

Professor

Default user image.

Recombinant antibodies to an oxidized low-density lipoprotein epitope induce rapid regression of atherosclerosis in apobec-1(-/-)/low-density lipoprotein receptor(-/-) mice.

Author

  • Alexandru Schiopu
  • Björn Frendéus
  • Bo Jansson
  • Ingrid Söderberg
  • Irena Ljungcrantz
  • Zufan Araya
  • Prediman K Shah
  • Roland Carlsson
  • Jan Nilsson
  • Gunilla Nordin Fredrikson

Summary, in English

OBJECTIVES: The present study tested the hypothesis that treatment with human recombinant immunoglobulin G1 (IgG1) antibodies against a specific oxidized low-density lipoprotein (oxLDL) epitope will induce regression of existing atherosclerotic lesions in LDL receptor-deficient mice expressing apolipoprotein B-100 (apoB-100) (Apobec-1(-/-)/LDLR(-/-)). BACKGROUND: Oxidized LDL plays an essential role in the pathogenesis of atherosclerosis. We previously showed that an antibody against oxLDL reduces progression of atherosclerosis in mice. METHODS: Apobec-1(-/-)/LDLR(-/-) mice were fed a high-fat diet until they were 24 weeks and were subsequently transferred to chow. Starting at 25 weeks, mice were given 3 weekly injections of either of 2 recombinant human IgG1 antibodies (IEI-E3 or 2D03) against a malondialdehyde-modified apoB-100 peptide sequence. RESULTS: At 25 weeks, atherosclerotic lesions covered 10.3 +/- 3.7% of the descending aorta. Transfer to chow diet resulted in a modest regression of atherosclerosis over a 5-week period (8.28 +/- 4.36%; p = NS). Antibody treatment induced additional regression of atherosclerosis by 50% (2D03; p = 0.001) and 36% (IEI-E3; p = 0.004) compared with control IgG1. The 2D03 treatment also reduced plaque inflammation, enhanced plaque expression of the adenosine triphosphate-binding cassette transporter A1, and inhibited expression of monocyte chemoattractant protein-1 in cultured monocytes. CONCLUSIONS: Human IgG1 against a specific oxLDL epitope can induce rapid and substantial regression of atherosclerotic lesions, possibly by stimulating lipid efflux and inhibiting macrophage recruitment. These recombinant human antibodies could represent a novel strategy for rapid regression/stabilization of atherosclerotic lesions.

Department/s

  • Cardiovascular Research - Immunity and Atherosclerosis

Publishing year

2007

Language

English

Pages

2313-2318

Publication/Series

Journal of the American College of Cardiology

Volume

50

Issue

24

Document type

Journal article

Publisher

Elsevier USA

Topic

  • Cardiac and Cardiovascular Systems

Keywords

  • Recombinant Proteins: therapeutic use
  • Oxidized LDL: physiology
  • Receptors
  • Peptide Fragments: immunology
  • Immunologic Factors: therapeutic use
  • Immunoglobulin G: therapeutic use
  • Cytidine Deaminase: physiology
  • Atherosclerosis: pathology
  • Atherosclerosis: metabolism
  • Atherosclerosis: drug therapy
  • ATP-Binding Cassette Transporters: metabolism
  • Apolipoprotein B-100: immunology

Status

Published

Research group

  • Cardiovascular Research - Immunity and Atherosclerosis

ISBN/ISSN/Other

  • ISSN: 0735-1097